The prescriber has changed the patient’s medication regimen to include the leukotriene receptor antagonist montelukast (Singulair) to treat asthma. The nurse will emphasize which point about this medication?
Rationale:
Montelukast needs to be taken every day on a continuous schedule, even if symptoms improve.
Montelukast is a controller medication that reduces inflammation and prevents asthma symptoms over time; consistent daily use ensures effectiveness. It is not designed for immediate relief but rather long-term management to maintain airway stability and prevent exacerbations, so adherence to a regular schedule is essential regardless of symptom presence.
A: The proper technique for inhalation must be followed. Montelukast is an oral tablet, not an inhaled medication, so inhalation technique is irrelevant.
B: The patient needs to keep it close by at all times to treat acute asthma attacks. Montelukast does not provide rapid relief for acute asthma attacks; it is for long-term control only.
D: When the asthma symptoms improve, the dosage schedule can be tapered and eventually discontinued. Asthma control medications like montelukast require ongoing use; premature discontinuation can lead to symptom recurrence or exacerbation.
What is the type of drug-to-drug interaction which is connected with processes of absorption, biotransformation,distribution and excretion?
Rationale:
Pharmacokinetic interaction is connected with processes of absorption, biotransformation, distribution, and excretion. This interaction type involves how drugs influence each other's movement through the body, affecting drug concentration and effect by altering metabolic pathways, transport mechanisms, or elimination rates, directly impacting therapeutic outcomes and toxicity risks during combined drug administration.
A: Pharmacodynamic interaction involves drug effects at target sites, not the movement or processing of drugs within the body. It focuses on the combined physiological outcomes rather than absorption or metabolism.
B: Physical and chemical interaction refers to direct chemical or physical changes between drugs outside the body, not involving absorption, metabolism, distribution, or excretion mechanisms within the organism.
C: Pharmaceutical interaction occurs when drugs interact before administration, such as during formulation or mixing, affecting stability but not processes like absorption, biotransformation, or elimination inside the body.
The mechanism of atropine action is:
Rationale:
Atropine acts by competitive muscarinic blockade. This means atropine selectively binds to muscarinic acetylcholine receptors without activating them, preventing acetylcholine from attaching and triggering parasympathetic responses. It does not affect nicotinic receptors found in ganglia or neuromuscular junctions, making its action specific to muscarinic sites, which explains its clinical uses in reducing secretions and treating bradycardia.
A: Competitive ganglion blockade Atropine does not target nicotinic receptors in autonomic ganglia; thus, it cannot block ganglionic transmission competitively. Ganglion blockers primarily affect both sympathetic and parasympathetic output, unlike atropine’s selective parasympathetic muscarinic receptor antagonism.
C: Competitive neuromuscular blockade Neuromuscular junctions involve nicotinic receptors on skeletal muscle, which atropine does not competitively antagonize. Neuromuscular blockers are distinct drugs used for muscle relaxation, unrelated to atropine’s parasympathetic effects.
D: Noncompetitive neuromuscular blockade Atropine does not cause irreversible or noncompetitive inhibition at neuromuscular junctions, which would involve permanent receptor inactivation or ion channel blockade, a mechanism unrelated to its reversible muscarinic receptor antagonism.
Indicate the sympathomimetic agent, which is combined with a local anesthetic to prolong the duration of infiltration nerve block:
Rationale:
Epinephrine is the sympathomimetic agent combined with local anesthetics to prolong infiltration nerve block duration. Epinephrine causes vasoconstriction, reducing local blood flow, which decreases anesthetic absorption into the bloodstream, thereby extending its effect at the injection site. This vasoconstrictive property is essential in maintaining effective anesthesia for longer periods during surgical or dental procedures.
B: Xylometazoline primarily serves as a nasal decongestant inducing localized vasoconstriction but is not used with local anesthetics to extend nerve block duration in infiltration anesthesia.
C: Isoproterenol acts mainly on beta-adrenergic receptors causing vasodilation and increased heart rate, which would counteract the goal of prolonging local anesthetic effects.
D: Dobutamine predominantly stimulates beta-1 receptors to increase cardiac output and does not produce the necessary vasoconstriction to prolong local anesthetic action.
Indicate the usual cause of death due to overdose of hypnotics:
Rationale:
Death due to overdose of hypnotics usually results from depression of the medullar respiratory center. Hypnotics primarily act by depressing central nervous system activity, especially targeting the brainstem's respiratory centers, leading to diminished respiratory drive. This respiratory failure causes hypoxia and eventual death if not promptly treated. Other complications are less directly lethal in typical overdose scenarios.
B: Hypothermia occurs due to decreased thermoregulation but does not directly cause death in hypnotic overdose; respiratory depression remains the critical fatal mechanism.
C: Cerebral edema is not a primary consequence of hypnotic overdose; the fatal risk lies in respiratory failure rather than brain swelling.
D: Status epilepticus involves continuous seizures, which hypnotics generally suppress rather than induce, making it an uncommon cause of death in this context.
Which of the following opioid analgesics can produce dysphoria,anxiety and hallucinations?
Rationale:
Pentazocine can produce dysphoria, anxiety, and hallucinations. Pentazocine is a mixed agonist-antagonist opioid that acts on kappa receptors, which are associated with dysphoric and psychotomimetic effects, unlike pure mu-opioid agonists. This pharmacologic profile explains why pentazocine may cause adverse psychological symptoms such as anxiety and hallucinations in some patients during analgesic treatment.
A: Morphine primarily acts as a pure mu-opioid agonist, producing euphoria and analgesia rather than dysphoria or hallucinations, making it unlikely to induce such adverse psychological effects.
B: Fentanyl is a potent mu-opioid receptor agonist that provides strong analgesia with minimal psychotomimetic side effects, thus it rarely causes anxiety or hallucinations.
D: Methadone, a long-acting mu-opioid agonist, is used for pain and opioid dependence without typically eliciting dysphoria, anxiety, or hallucinations associated with kappa receptor activation.
Which of the following antidepressant agents is a selective inhibitor of norepinephrine reuptake?
Rationale:
Maprotiline is a selective inhibitor of norepinephrine reuptake. This agent primarily targets norepinephrine transporters, increasing norepinephrine availability in synaptic clefts, which enhances mood and alleviates depressive symptoms. Unlike other antidepressants, maprotiline’s selectivity minimizes serotonin transporter interaction, distinguishing it pharmacologically and clinically within the class of norepinephrine reuptake inhibitors.
A: Fluvoxamine primarily inhibits serotonin reuptake and has minimal effect on norepinephrine, focusing mainly on serotonergic pathways rather than selective norepinephrine transporter inhibition.
C: Amitriptyline blocks both serotonin and norepinephrine reuptake non-selectively, lacking specificity exclusively for norepinephrine transporters.
D: Tranylcypromine inhibits monoamine oxidase enzymes, increasing monoamine levels broadly rather than selectively blocking norepinephrine reuptake.
Which of the following abused drugs do not belong to sedative agents?
Rationale:
Cannabinoids do not belong to sedative agents among the abused drugs listed.
Cannabinoids primarily act on the endocannabinoid system producing psychoactive effects such as altered perception and mood, rather than primarily inducing sedation. Unlike sedatives, cannabinoids do not predominantly depress central nervous system activity to cause relaxation or sleepiness, distinguishing them from barbiturates, tranquilizers, and opioids, which all have sedative properties.
A: Barbiturates Depress the central nervous system significantly, causing sedation, hypnosis, and anesthesia, fitting squarely into sedative agents.
B: Tranquilizers Reduce anxiety and induce calmness through CNS depression, clearly classifying them as sedative drugs.
D: Opioids Primarily relieve pain and produce sedation by depressing the CNS, aligning with sedative drug characteristics.
Tick the mechanism of Metoclopramide antiemetic action:
Rationale:
Metoclopramide acts as an antiemetic by blocking D2-dopamine and 5-HT3-serotonin receptors. This dual receptor antagonism reduces nausea and vomiting by inhibiting signals in the chemoreceptor trigger zone and gastrointestinal tract, effectively controlling emesis through central and peripheral mechanisms. Its unique receptor profile distinguishes it from other antiemetics.
A: H1 and H2-receptor blocking effect pertains mainly to antihistamines, not metoclopramide, which does not target these receptors for antiemetic action.
B: M-cholinoreceptor stimulating effect involves parasympathetic activation, unrelated to metoclopramide’s antiemetic mechanism focused on dopamine and serotonin receptors.
D: M-cholinoblocking effect relates to anticholinergic drugs, whereas metoclopramide’s efficacy arises from dopaminergic and serotonergic receptor antagonism, not muscarinic blockade.
This drug group useful in angina decreases myocardial oxygen requirement (by decreasing the determinations of oxygen demand) and does not increase myocardial oxygen delivery (by reversing coronary arterial spasm):
Rationale:
Beta-adrenoceptor-blocking drugs (Atenolol, Metoprolol) decrease myocardial oxygen requirement by reducing heart rate and contractility without increasing oxygen delivery through coronary artery dilation.
These drugs lower oxygen demand by diminishing cardiac workload and do not reverse coronary arterial spasm, thereby effectively managing angina by controlling demand rather than enhancing supply. This mechanism directly addresses oxygen consumption rather than delivery.
A: Nitrates and nitrite drugs primarily increase oxygen delivery by dilating coronary arteries and relieving spasm, thus not fitting the question’s criteria of no increased oxygen delivery.
B: Myotropic coronary dilators like Dipyridamole mainly improve oxygen supply by vasodilation, which contradicts the requirement of not increasing myocardial oxygen delivery.
C: Potassium channel openers such as Minoxidil act mainly as vasodilators, enhancing oxygen delivery rather than decreasing oxygen demand in angina management.
Oxytocin produces the following effects:
Rationale:
Oxytocin produces all the effects listed: it causes uterine contractions, assists spermatozoa movement into the uterine cavity, and triggers milk ejection from the lactating mammary gland. This hormone plays a multifaceted role in reproductive physiology, facilitating childbirth, promoting fertilization, and enabling breastfeeding by stimulating smooth muscle contractions and myoepithelial cell activity.
A: It causes contraction of the uterus but does not encompass oxytocin’s additional roles in sperm transport and milk ejection, making this choice incomplete.
B: It assists spermatozoa progress but excludes critical functions like uterine contractions and milk ejection, thus not fully representing oxytocin’s range.
C: It brings about milk ejection but overlooks oxytocin’s key involvement in uterine contractions and aiding sperm movement, so it is insufficient alone.
Ketorolac is an NSAID that is promoted for systemic use as an anti-inflammatory, not as an analgesic drug. This statement is:
Rationale:
Ketorolac is not promoted solely for systemic anti-inflammatory use but is primarily recognized as a potent analgesic. Ketorolac is widely used for its strong pain-relieving effects, particularly in postoperative settings, rather than for its anti-inflammatory properties. Its analgesic efficacy surpasses its anti-inflammatory benefits, distinguishing it from many other NSAIDs typically used for inflammation control.
A: TRUE This option inaccurately portrays ketorolac’s clinical application, emphasizing anti-inflammatory use, which contradicts its primary indication as a powerful systemic analgesic rather than an anti-inflammatory agent.
C: None This choice is irrelevant because the question demands a true or false evaluation, making “None” an inapplicable and nonsensical response in this context.
D: All of the above This option illogically combines mutually exclusive answers, failing logically since the statement cannot be both true and false simultaneously.
Which of the following coenzymes is of vitamin origin?
Rationale:
Piridixal-5-phosphate is a coenzyme derived from vitamin B6, making it of vitamin origin. This compound serves as an active form of vitamin B6, playing a crucial role in amino acid metabolism and enzyme function, distinguishing it from non-vitamin-derived coenzymes. Its vitamin basis ensures essential biochemical processes depend on dietary intake for proper enzymatic activity and physiological balance.
A: Riboxine lacks recognition as a vitamin-derived coenzyme; it is not involved in enzymatic processes linked to vitamin metabolism, thus it does not qualify as a vitamin-origin coenzyme.
B: Coenzyme Q10 is synthesized endogenously and is not a vitamin derivative, functioning mainly in electron transport without being directly sourced from vitamins in the diet.
D: Lipoic acid, although a cofactor, is not derived from vitamins; it is a sulfur-containing compound synthesized by the body, unrelated to vitamin origin in coenzyme context.
Indication for cholecalciferol administration is:
Rationale:
Cholecalciferol administration is indicated in malabsorption of vitamin D from the intestine. This condition impairs vitamin D absorption, leading to deficiency, which cholecalciferol supplementation corrects by restoring adequate vitamin D levels, essential for calcium homeostasis and bone health. It compensates for decreased intestinal absorption, preventing complications like osteomalacia and supporting proper metabolic functions dependent on vitamin D.
A: Hypercalcemia involves elevated calcium levels; administering cholecalciferol would exacerbate calcium overload, risking toxicity rather than correction.
B: Parathyroid hormone deficiency reduces calcium regulation, but cholecalciferol alone does not replace hormone function; treatment focuses on hormone replacement or calcium management.
C: Primary hyperparathyroidism causes excess parathyroid hormone; adding cholecalciferol risks increasing calcium absorption, worsening hypercalcemia instead of providing therapeutic benefit.
Tick the drug belonging to nitrobenzene derivative:
Rationale:
Chloramphenicol belongs to the nitrobenzene derivative class of drugs. This antibiotic contains a nitrobenzene moiety in its chemical structure, which distinguishes it from others. Nitrobenzene derivatives are characterized by the presence of a nitro group attached to a benzene ring, integral to chloramphenicol’s antimicrobial activity by inhibiting protein synthesis at the bacterial ribosome level.
A: Clindamycin lacks a nitrobenzene structure; it is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
B: Streptomycin is an aminoglycoside antibiotic without a nitrobenzene group, functioning by causing misreading of mRNA during bacterial protein synthesis.
C: Azithromycin is a macrolide antibiotic unrelated to nitrobenzene derivatives, acting by binding to the 50S ribosomal subunit to block bacterial protein elongation.
Tick the drug for trematodosis (fluke invasion) treatment:
Rationale:
Bithionol is the drug used for treating trematodosis (fluke invasion). Bithionol specifically targets liver and lung flukes by disrupting their metabolic processes, making it effective against trematodes. It has been historically and clinically validated for this parasitic infection, distinguishing it from drugs tailored to nematodes or protozoan infections, ensuring targeted and effective therapy for fluke infestations.
B: Ivermectin primarily acts against nematodes and some ectoparasites; it lacks efficacy against trematodes, rendering it unsuitable for fluke infections.
C: Pyrantel is an anthelmintic targeting intestinal nematodes, not trematodes, thus irrelevant for treating fluke invasions.
D: Metronidazole treats anaerobic bacterial and protozoal infections, without significant activity against trematodes, making it ineffective for fluke treatment.
What enzyme cleaves plasminogen to form active plasmin?
Rationale:
Plasmin cleaves plasminogen to form active plasmin. Plasminogen is an inactive zymogen converted to plasmin, a serine protease responsible for fibrinolysis. This conversion is catalyzed by plasmin itself in an autocatalytic process, amplifying plasmin formation and facilitating the breakdown of fibrin clots efficiently, crucial for maintaining vascular patency and preventing thrombosis.
B: Fibrinogen serves as a substrate for clot formation, not an enzyme catalyzing plasminogen activation. It is a soluble plasma glycoprotein converted by thrombin into fibrin during coagulation, unrelated to the cleavage of plasminogen.
C: Thrombin is a protease that converts fibrinogen to fibrin in clot formation but does not cleave plasminogen. Its role is pro-coagulant rather than fibrinolytic, thus not responsible for producing active plasmin.
D: Streptokinase is a bacterial protein that activates plasminogen indirectly but does not enzymatically cleave plasminogen itself. It forms a complex with plasminogen to initiate plasmin generation, differing mechanistically from plasmin’s direct cleavage.
A patient on oral anticoagulant therapy is commenced on sulfamethoxazole-trimethoprim, double-strength twice daily. One may expect to see the international normalized ratio
Rationale:
The international normalized ratio (INR) is expected to increase. Sulfamethoxazole-trimethoprim inhibits the metabolism of warfarin, an oral anticoagulant, by interfering with cytochrome P450 enzymes. This interaction enhances warfarin's anticoagulant effect, leading to a higher INR and increased bleeding risk, necessitating careful monitoring and possible dose adjustment to maintain therapeutic anticoagulation safely.
B: Decrease Sulfamethoxazole-trimethoprim does not induce warfarin metabolism; rather, it inhibits it. Therefore, the INR would not decrease, as the anticoagulant effect is potentiated, not diminished, preventing any reduction in INR values.
C: Remain unchanged Sulfamethoxazole-trimethoprim affects warfarin metabolism, altering its anticoagulant potency. Consequently, the INR will not remain stable but will increase, reflecting enhanced anticoagulant activity and requiring vigilant monitoring.
The client is on hydrochlorothiazide and digoxin. What effect can the nurse expect?
Rationale:
Hydrochlorothiazide decreases potassium, increasing the risk of digoxin toxicity.
Hydrochlorothiazide is a diuretic that promotes potassium excretion, leading to hypokalemia. Low potassium levels enhance digoxin’s effects and toxicity risk because digoxin competes with potassium at cell binding sites, making this interaction clinically significant for monitoring and managing patient safety.
A: Hydrochlorothiazide increases digoxin levels. This option mistakenly attributes a direct increase in digoxin concentration, which does not occur; the risk is due to potassium imbalance, not altered drug serum levels.
B: Hydrochlorothiazide decreases digoxin levels. This choice incorrectly suggests reduced digoxin efficacy or serum concentration, which is not accurate; hydrochlorothiazide affects potassium, not digoxin blood levels.
D: Digoxin can increase the effectiveness of hydrochlorothiazide. This statement inaccurately implies digoxin enhances the diuretic effect, which is unsupported by pharmacological evidence or clinical practice guidelines.
A 58-year-old woman who is obese presents to the emergency department with diaphoresis and crushing chest pain that radiates to her left arm. The physician orders an ECG and checks her cardiac enzymes to confirm his suspicion of myocardial infarction. Because of the quick response and intervention, she survives and is ultimately discharged with a prescription for low-dose daily aspirin to inhibit platelet aggregation. Two weeks after discharge, she takes ibuprofen for a tension headache. What is the effect of the ibuprofen on her anticoagulation regimen?
Rationale:
Ibuprofen causes insufficient antiplatelet activity because it competitively inhibits platelet cyclooxygenase, interfering with aspirin’s irreversible inhibition and reducing its effectiveness.
D: Ibuprofen reversibly binds platelet cyclooxygenase before aspirin can irreversibly inhibit it, leading to inadequate suppression of thromboxane A2 and diminished antiplatelet effect in this patient’s regimen.
A: Ibuprofen and aspirin do not synergistically enhance platelet inhibition; rather, ibuprofen antagonizes aspirin’s action by competing for the same enzyme, preventing excessive antiplatelet activity.
B: Ibuprofen’s primary effect is on platelet cyclooxygenase, not endothelial cells; thus, combined effects on endothelium and platelets do not cause excessive antiplatelet activity.
C: Ibuprofen does not induce cytochrome P450 enzymes responsible for aspirin metabolism; therefore, aspirin’s clearance remains unaffected, and insufficient antiplatelet activity arises from enzyme competition, not increased metabolism.
A 58-year-old man with diabetes has difficulty achieving an erection. He has a history of cardiovascular disease. A friend recommends yohimbine. Which of the following describes yohimbine's likely mechanism of action?
Rationale:
Yohimbine works by increasing sympathetic tone. It primarily acts as an alpha-2 adrenergic receptor antagonist, which enhances norepinephrine release, thereby increasing sympathetic nervous system activity. This increase in sympathetic tone can improve erectile function by promoting penile blood flow. Yohimbine's mechanism is distinct from direct vascular effects, instead modulating autonomic nervous system balance to facilitate erection in patients with erectile dysfunction.
A: Decreasing parasympathetic tone would reduce erection capacity since parasympathetic activation is essential for initiating penile vasodilation. Yohimbine does not inhibit parasympathetic activity but rather influences sympathetic pathways.
B: Direct vasoconstriction would worsen erectile function by limiting blood flow to the penis. Yohimbine does not constrict blood vessels but modulates neural input to improve blood flow.
C: Direct vasodilation is not the primary action of yohimbine; it does not directly relax vascular smooth muscle but increases norepinephrine release, affecting sympathetic tone rather than causing immediate vasodilation.
The following may increase digitalis toxicity EXCEPT:
Rationale:
Spironolactone does not increase digitalis toxicity. Spironolactone is a potassium-sparing diuretic that helps maintain potassium levels, reducing the risk of hypokalemia, which is a key factor in increasing digitalis toxicity. Unlike other diuretics that cause potassium loss, spironolactone’s potassium-retaining effect protects against enhanced digitalis toxicity by preventing dangerous electrolyte imbalances.
A: Furosemide causes potassium depletion, leading to hypokalemia, which enhances digitalis toxicity by increasing its effects on cardiac cells, raising the risk of arrhythmias and toxicity symptoms.
B: Chlorothiazide promotes potassium loss through increased renal excretion, which potentiates digitalis effects and elevates toxicity risk by causing electrolyte disturbances.
D: Verapamil inhibits P-glycoprotein, reducing digitalis clearance and increasing serum levels, thus potentiating digitalis toxicity through pharmacokinetic interactions affecting drug metabolism.
The nurse understands that the purpose for chlorpromazine (Thorazine) is to:
Rationale:
Chlorpromazine (Thorazine) is used to reduce psychotic symptoms. This medication is a typical antipsychotic that works by blocking dopamine receptors in the brain, thereby diminishing hallucinations, delusions, and disorganized thinking often present in schizophrenia and other psychotic disorders. Its primary function is symptom management rather than sedation or prevention of side effects.
A: Ensure that the client can get enough sleep. This option confuses chlorpromazine’s sedative side effects with its therapeutic purpose, which is not primarily to induce sleep but to alleviate psychosis.
C: Increase levels of dopamine in the brain. Chlorpromazine actually blocks dopamine receptors, reducing dopamine activity rather than increasing it, to control psychotic symptoms effectively.
D: Prevent extrapyramidal symptoms. This medication may cause extrapyramidal symptoms; it does not prevent them but is associated with these adverse effects as a common risk.
A patient’s blood pressure is 130/84. The health care provider plans to suggest nonpharmacologic methods to lower blood pressure. Which should the nurse include in teaching? (Select ALL that apply.)
Rationale:
Stress-reduction techniques should be included in teaching to help lower blood pressure nonpharmacologically. Managing stress reduces sympathetic nervous system activation, which can elevate blood pressure. Techniques like meditation, deep breathing, or yoga promote relaxation and improve cardiovascular health, making them effective strategies for blood pressure control without medication, especially for patients with mildly elevated readings such as 130/84 mm Hg.
B: An exercise program enhances cardiovascular fitness but is not specifically emphasized here as the primary nonpharmacologic method for this patient’s blood pressure management.
C: Salt restriction is beneficial for some hypertensive patients but not explicitly recommended in this scenario for the blood pressure level given.
D: Smoking cessation improves overall health but does not directly lower blood pressure in the immediate context of nonpharmacologic interventions.
In order to effectively provide appropriate patient teaching regarding the effects of psychotropic medications, an advanced practice nurse with prescriptive privileges is required to have a thorough understanding of which drug-related topic?
Rationale:
A thorough understanding of clinical indicators is essential for an advanced practice nurse to provide appropriate patient teaching about psychotropic medications. Clinical indicators guide the nurse in recognizing symptoms, monitoring treatment effects, and making informed decisions tailored to each patient’s condition, ensuring safe and effective medication management aligned with therapeutic goals and individual patient needs.
B: Pharmacology algorithms refer to systematic treatment pathways but do not encompass the comprehensive patient-specific knowledge required for teaching about psychotropic medication effects and management in clinical practice.
C: Monotherapeutic symptoms focus narrowly on single drug effects, lacking the broader clinical context and symptom recognition necessary for comprehensive patient education on psychotropic medications.
D: Knowing doses of all atypical psychotropic drugs overlooks the importance of interpreting clinical indicators and patient responses, which are crucial for effective teaching and individualized medication management.
A 29-year-old male patient is admitted to the intensive care unit with the following symptoms: restlessness, hyperactive reflexes, talkativeness, confusion and periods of panic and euphoria, tachycardia, and fever. The nurse suspects that he may be experiencing the effects of taking which substance?
Rationale:
The patient is experiencing the effects of taking stimulants. Stimulants increase central nervous system activity, causing symptoms like restlessness, hyperactive reflexes, confusion, tachycardia, fever, and mood changes such as panic and euphoria. These signs align closely with stimulant intoxication or overdose, differentiating it from other substance categories.
A: Opioids typically cause respiratory depression, sedation, and pinpoint pupils, which contrasts with the patient’s hyperactive and agitated presentation.
B: Alcohol intoxication generally leads to sedation, impaired coordination, and slurred speech, not the hyperactivity and confusion seen here.
D: Depressants induce CNS depression, leading to drowsiness and decreased reflexes, opposite of the hyperactivity and tachycardia observed.
After receiving a nebulizer treatment with a beta agonist, the patient complains of feeling slightly nervous and wonders if her asthma is getting worse. What is the nurse’s best response?
Rationale:
This is an expected adverse effect. Let me take your pulse.
Beta agonists commonly cause nervousness as a side effect due to their stimulant properties. Monitoring the pulse helps assess cardiovascular response and ensures patient safety. Reassuring the patient while performing this assessment addresses concerns and prevents unnecessary alarm about asthma worsening, aligning with standard nursing protocols after nebulizer treatments.
B: The next scheduled nebulizer treatment will be skipped. Skipping treatment without evaluation risks uncontrolled asthma symptoms. Nervousness alone does not warrant omission of therapy unless severe adverse effects occur.
C: I will notify the physician about this adverse effect. Mild nervousness is typical and usually does not require immediate physician notification. The nurse’s priority is assessment and reassurance before escalation.
D: We will hold the treatment for 24 hours. Halting treatment unnecessarily may worsen asthma control. Nervousness is expected and transient, so continuing therapy with monitoring is preferable to interruption.
What is the type of drug-to-drug interaction which is the result of interaction at receptor, cell, enzyme or organ level?
Rationale:
Pharmacodynamic interaction is the type of drug-to-drug interaction resulting from interactions at receptor, cell, enzyme, or organ levels. Pharmacodynamic interactions occur when drugs influence each other's effects directly within the body’s biological systems, altering therapeutic outcomes by modifying receptor activities, cellular responses, enzyme functions, or organ performance, thereby impacting drug efficacy or toxicity without changing drug concentrations.
B: Physical and chemical interaction involves direct mixing of drugs leading to visible or chemical changes, not interactions at biological targets like receptors or enzymes.
C: Pharmaceutical interaction refers to incompatibilities during drug formulation or preparation, unrelated to biological or cellular mechanisms.
D: Pharmacokinetic interaction concerns absorption, distribution, metabolism, or excretion alterations, not direct effects at receptor or organ levels.
The tissues most sensitive to atropine are:
Rationale:
The tissues most sensitive to atropine are the salivary, bronchial and sweat glands. Atropine predominantly blocks muscarinic receptors in exocrine glands, reducing secretions like saliva, bronchial mucus, and sweat. These glands exhibit high receptor density, making them more responsive to atropine’s anticholinergic effects compared to other tissues, resulting in pronounced drying and reduced glandular secretions.
B: The gastric parietal cells have muscarinic receptors but show less sensitivity to atropine, as their secretory response is modulated by multiple factors including histamine and gastrin, diminishing atropine’s relative effect.
C: Smooth muscle and autonomic effectors respond to atropine but require higher doses for inhibition; their variable receptor types and indirect neural influences reduce sensitivity compared to exocrine glands.
D: The heart contains muscarinic receptors but exhibits moderate atropine sensitivity; cardiac effects manifest at different dose thresholds and are less pronounced than glandular secretory inhibition.
Which of the following sympathomimetics is related to short-acting topical decongestant agents?
Rationale:
Phenylephrine is related to short-acting topical decongestant agents. Phenylephrine acts as a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction in nasal mucosa, which reduces swelling and congestion. Its rapid onset and short duration make it suitable for brief relief of nasal congestion, distinguishing it from longer-acting or systemic sympathomimetics used in other clinical contexts.
A: Xylometazoline primarily functions as a long-acting topical decongestant due to its prolonged vasoconstrictive effects, making it unsuitable as a short-acting agent. Its pharmacodynamics differ significantly from phenylephrine’s duration.
B: Terbutaline mainly serves as a bronchodilator targeting beta-2 receptors, not as a topical nasal decongestant. Its therapeutic use focuses on respiratory conditions rather than nasal congestion relief.
D: Norepinephrine acts as a systemic vasopressor with potent alpha and beta effects, unsuitable for topical nasal application due to its potent systemic cardiovascular actions and lack of targeted short-term nasal decongestion.